CTIS2023-503256-27-00
Recruiting
Phase 1
Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency. - PANC-GRP-3001
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- patients with cystic fibrosis suffering from pancreatic exocrine insufficiency
- Sponsor
- MEDA Pharma GmbH & Co. KG
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male and female subjects of any ethnic origin, At least 18 years of age, Cystic fibrosis (documented by two sweat tests or by gene analysis), On treatment with PERT with CREON capsules on the current dose for at least 4 weeks prior to entry in the study and with satisfactory symptom control (e.g. stool frequency and consistency, meteorism/flatulence, abdominal pain) with a dose of at least two CREON capsules per main meal, Willing to comply with the requirements of the study protocol., Written informed consent.
Exclusion Criteria
- •Evidence of severe disease, or any other relevant condition (other than CF) as revealed by history or physical examination which might limit participation in or completion of the study., Anticipated non\-availability for study visits/procedures., Vulnerable subjects (such as persons kept in detention)., Lack of ability or willingness to give informed consent., History of allergic reaction or hypersensitivity to pancreatin or excipients of CREON or any porc or pig product., Known predisposition to allergies., Positive ß\-human chorionic gonadotropin (HCG) pregnancy test, established pregnancy, or breast\-feeding at Visit V1\. Women of childbearing potential not using at least one effective method of contraception (preferably one whose effectiveness is not dependent on the user, such as an intrauterine device or implant)., Clinically relevant acute infections, febrile disease, or any acute condition (illness) two weeks prior to Visit 1 (V1\), as judged by the investigator., History of alcohol or drug abuse within the last 2 years., Exposure to another investigational product within the last three months., Lack of willingness to have personal study\-related data collected, archived or transmitted according to protocol., Lack of willingness or inability to co\-operate adequately.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Clinical study to evaluate the handling and safety of AVT06 PFS in subjects with chorioretinal vascular disease (ALVOEYE-D).chorioretinal vascular disease (neovascular age-related macular degeneration [nAMD], diabetic macular edema [DME], myopic choroidal neovascularization [CNV], retinal vein occlusion [RVO] and diabetic retinopathy [DR])MedDRA version: 20.1Level: PTClassification code: 10012689Term: Diabetic retinopathy Class: 100000004853MedDRA version: 20.0Level: PTClassification code: 10071129Term: Neovascular age-related macular degeneration Class: 100000004853MedDRA version: 20.0Level: PTClassification code: 10038907Term: Retinal vein occlusion Class: 100000004853MedDRA version: 20.1Level: LLTClassification code: 10057934Term: Diabetic macular edema Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10073711Term: Myopic choroidal neovascularization Class: 10015919Therapeutic area: Diseases [C] - Eye Diseases [C11]CTIS2023-505225-13-00Alvotech Swiss AG35
Recruiting
Not Applicable
Multicenter study for the interval of surveillance colonoscopy after polypectomyNeoplasmsKCT0000059Hanyang University Guri Hospital2,000
Completed
Phase 2
Clinical trial of Mycobacterium w in Combination withPaclitaxel and Cisplatin in Advanced non small cell lung cancer patients.Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungCTRI/2007/091/000037Cadila Pharmaceuticals ltd221
Completed
Not Applicable
Multicentre, open-label randomised clinical trial of efficacy and tolerability of the fixed-dose artesunate/amodiaquine (AS/AQ) combination therapy and amodiaquine (AQ) monotherapy for treatment of uncomplicated falciparum malaria in IndiaISRCTN84408319Drugs for Neglected Diseases initiative (DNDi) (Switzerland)300
Recruiting
Phase 2
The efficacy of delgocitinib ointment for rosacea and rosacea-like dermatitisJPRN-jRCTs061210078Kajita Ai30